UCB S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jean-Christophe Tellier
- Full Time Employees
- 10,117
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Allée de la Recherche, 60 Brussels BU Belgium 1070
- IPO Date
- Aug 26, 2008
- Website
- ucb.com
- Similar Companies
- Business
- UCB SA is a global biopharmaceutical company focused on developing and commercializing innovative medicines for immunology, neurology, and dermatology disorders. The company offers a portfolio of branded products including Cimzia (certolizumab pegol) for inflammatory autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and non-radiographic axial spondyloarthritis; Evenity (romosozumab) for osteoporosis in postmenopausal women at high risk for fracture; Briviact (brivaracetam) for partial-onset seizures in epilepsy patients; Nayzilam (midazolam) nasal spray for acute treatment of seizure clusters; and Vyvey (eptinezumab) for migraine prevention, along with other therapies like Nozinan and Zeposia. UCB SA operates in over 40 countries with manufacturing facilities in Europe, North America, and Asia, targeting patients, healthcare providers, and partners in the biopharma sector. Founded in 1928 and headquartered in Brussels, Belgium, the company maintains subsidiaries worldwide and continues to advance its pipeline through research in severe diseases. In recent developments, UCB completed the acquisition of Zogenix in 2023 to bolster its neurology portfolio with Xcopri (cenobamate) for epilepsy; launched Vyvey in multiple European markets in 2022-2023 for migraine; reported positive Phase 3 results for rozanolixizumab in myasthenia gravis in 2023 leading to regulatory filings; and announced a strategic partnership with Roche in 2024 for bispecific antibody development in immunology.
United Community Banks, Inc. (UCB) Q2 2026 Earnings Call Transcript
United Community Banks (UCB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
United Community Banks (UCB) Q2 Earnings and Revenues Miss Estimates
UCB: From Rebuild To Re-Rating (Initiating Buy)
United Community Banks (UCB) Earnings Expected to Grow: Should You Buy?
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
United Community Banks, Inc. (UCB) M&A Call Transcript
Veeva Expands Safety Suite Footprint With UCB Pharmacovigilance Deal
UCB SA (UCBJY) Analyst/Investor Day Transcript
UCB Unifies Global Pharmacovigilance Operations with Veeva Safety Suite
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
United Community Banks, Inc. (UCB) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About United Community Banks (UCB) Q1 Earnings
United Community Banks (UCB) Q1 Earnings and Revenues Miss Estimates
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
United Community Banks (UCB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Why United Community Banks (UCB) is a Great Dividend Stock Right Now
Why United Community Banks (UCB) is a Top Dividend Stock for Your Portfolio